EDMONTON, Dec. 12 /PRNewswire-FirstCall/ - Isotechnika Inc. announced today that Dr. Robert Foster, Isotechnika's Executive Chairman, will participate in a panel discussion at the RBC Capital Markets Health Care Conference. The conference will take place December 13-14, 2006 at the Westin Times Square Hotel in New York City. Dr. Foster's panel discussion titled "Skin Deep: The Future of Clinical Dermatology" is scheduled for Wednesday, December 13th at 1:30 p.m. EST/11:30 a.m. MST in the Majestic Ballroom 1 room.
All interested parties will be able to listen to the panel discussion via web cast by using the following link, http://www.wsw.com/webcast/rbc62/panel11. The web cast will be audio-only and will be archived for 30 days following the conference.
Edmonton-based Isotechnika Inc. is an international biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Isotechnika's lead compound, ISA247 has successfully completed a Canadian Phase III trial for the treatment of moderate to severe psoriasis. ISA247 is currently being investigated in a combined Phase III European/Canadian psoriasis trial and a Phase IIb North American Phase trial for the prevention of organ rejection following kidney transplantation.
Forward-Looking Statements
--------------------------
This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.
Isotechnika Inc.CONTACT: Stephanie Gillis-Paulgaard, Director, Corporate Communications,Isotechnika Inc., (780) 487-1600 (243), (780) 484-4105 (fax),sgillis-paulgaard@isotechnika.com
